Melatonin and Breast Cancer: Safety, Benefits, and Current Research

Melatonin is widely used as a sleep aid, but emerging research suggests it may also play a role in breast‑cancer prevention, tumor‑growth inhibition, and treatment tolerance.

For most women undergoing breast‑cancer therapy, melatonin appears safe, yet it can interact with certain prescription drugs. Consulting an oncologist before starting supplementation is essential.

This review summarizes the most recent scientific findings on melatonin’s potential to prevent breast cancer, slow tumor progression, and enhance conventional treatments.

Prevention

A 2018 systematic review highlighted melatonin’s anti‑estrogenic and antioxidant actions as possible mechanisms for reducing breast‑cancer risk. A 2021 update reached a similar conclusion, noting consistent signals across earlier studies that melatonin may modestly lower incidence.

Growth Suppression

Ex‑vivo experiments have shown that melatonin can inhibit a key signaling pathway implicated in triple‑negative breast cancer (TNBC), thereby limiting the cells’ proliferative capacity.

A 2025 meta‑analysis reported that daily doses of 3–20 mg of melatonin were associated with reduced tumor growth and lower rates of metastasis in preclinical models.

Additional laboratory work suggests melatonin’s anticancer activity may extend beyond breast tissue, positioning it as a broad‑spectrum oncologic agent under investigation.

Treatment Support

While definitive clinical trials are still lacking, a 2021 review of existing data indicated that melatonin could enhance the efficacy of chemotherapy and improve patients’ tolerance to treatment.

Safety and Drug Interactions

Melatonin is generally well tolerated during breast‑cancer therapy, but it may interact with medications such as anticoagulants, antihypertensives, and certain antidepressants. No direct interactions with standard chemotherapy agents have been reported.

Long‑term use has not been fully evaluated; chronic supplementation might influence hormonal balance, which could be relevant for some patients.

Always discuss melatonin use with your oncologist, especially if you are taking other prescription drugs.

Potential Mood and Sleep Benefits

Some patients report improved sleep quality, reduced anxiety, and lower stress levels when taking melatonin alongside cancer treatment. These observations are anecdotal and have not yet been confirmed by large‑scale studies.

Supplement Guidance for Breast‑Cancer Patients

Supplements generally considered safe: Vitamin D, calcium, and certain omega‑3 formulations, provided they are approved by your care team.

Supplements to use with caution or avoid: High‑dose green tea extracts, certain probiotics, and grapefruit juice, which have been linked to adverse effects when combined with chemotherapy.

Supplement choices should be individualized based on your specific treatment regimen and discussed with your healthcare provider.

Key Takeaways

• Current evidence suggests melatonin may lower breast‑cancer risk and impede tumor growth, but definitive proof is still pending.
• Typical supplemental doses range from 3 mg to 20 mg per day; higher doses have not been extensively studied in humans.
• Melatonin is safe for most patients, but potential drug interactions warrant medical review.
• No major health agency has issued formal recommendations on melatonin for breast‑cancer prevention or treatment.

In summary, melatonin shows promise as a supportive agent in breast‑cancer care, yet more rigorous clinical trials are needed to establish clear guidelines.